Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Intraretinal hyper-reflective foci (IHRF) are optical coherence tomography (OCT) risk factors for progression of age-related macular degeneration (AMD). In this study we assess the change in the number and distribution of IHRF over two years.
Methods: The axial distribution of IHRF were quantified in eyes with intermediate AMD (iAMD) at baseline and 24 months, using a series of 5 sequential equidistant en face OCT retinal slabs generated between the outer border of the internal limiting membrane (ILM) and the inner border of the retinal pigment epithelium (RPE). Following thresholding and binarization, IHRF were quantified in each retinal slab using ImageJ. The change in IHRF number in each slab between baseline and month 24 was calculated.
Results: Fifty-two eyes showed evidence of IHRF at baseline, and all continued to show evidence of IHRF at 24 months (M24). The total average IHRF count/eye increased significantly from 4.67 ± 0.63 at baseline to 11.62 ± 13.86 at M24 ( < 0.001) with a mean increase of 6.94 ± 11.12 (range: - 9 to + 60). Overall, at M24, 76.9% eyes showed an increase in IHRF whereas 15.4% of eyes showed a decrease (3 eyes [5.7%] showed no change). There was a greater number of IHRF and a greater increase in IHRF over M24 in the outer slabs.
Conclusions: IHRF are most common in the outer retinal layers and tend to increase in number over time. The impact of the distribution and frequency of these IHRF on the overall progression of AMD requires further study.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/02713683.2024.2343334 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Purpose: To assess how transitioning from an Aflibercept to a Faricimab intravitreal treatment impacts retinal structures and functional aspects in patients with neovascular age related macular degeneration (nAMD) in a real-life setting.
Patients And Methods: A retrospective clinical study including 49 patients (57 eyes) with nAMD at the Department of Ophthalmology and Optometry, Kepler University Hospital, Linz, Austria was performed. The patients, who had previously been receiving monthly Aflibercept injections with an unsatisfactory treatment response, were switched to intravitreal Faricimab and followed-up between 12/2022 and 12/2023.
Purpose: To explore the association between early response of different lesions and the number of anti-vascular endothelial growth factor (anti-VEGF) injections in neovascular age-related macular degeneration (nAMD).
Methods: This prospective study included treatment-naïve nAMD eyes with a 2-year follow-up period. Volumetric changes of multiple lesions during the loading phase were documented, including subretinal fluid (SRF), intraretinal fluid (IRF), vascular subretinal hyper-reflective material (vSHRM) and avascular subretinal hyper-reflective material, fibrovascular pigment epithelial detachment and serous pigment epithelial detachment (sPED) and total lesion.
Author Response: Letter to the Editor Regarding "Intraretinal Hyper-Reflective Foci Are Almost Universally Present and Co-Localize With Intraretinal Fluid in Diabetic Macular Edema".
Invest Ophthalmol Vis Sci
August 2025
Roche Pharma Research and Early Development, Roche Innovation Center Basel, F. Hoffmann-La Roche Ltd., Basel, Switzerland.
SD-OCT-based biomarkers in predicting treatment outcomes of macular oedema secondary to retinal vein occlusion treated with anti-VEGF therapy.
Acta Ophthalmol
August 2025
Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Hong Kong Special Administrative Region, China.
Purpose: To investigate the role of spectral domain optical coherence tomography (SD-OCT)-based biomarkers in predicting treatment response of macular oedema (MO) secondary to retinal vein occlusion (RVO) to anti-vascular endothelial growth factor (VEGF) therapy.
Methods: Retrospective cohort study including consecutive cases of RVO associated MO who received anti-VEGF injections between January 2020 and April 2021. LogMAR visual acuity (VA) at baseline, 12 and 24 months was correlated with a panel of SD-OCT-based biomarkers, including vitreomacular status, size of intra-retinal cysts (IRC), presence of disorganization of retinal inner layers (DRIL), hyper-reflective foci (HRF) in the retina, integrity of the external limiting membrane (ELM), ellipsoid zone (EZ), cone outer segment tip (COST) and presence of subretinal fluid (SRF).
Efficacy of Intravitreal Brolucizumab Switch in Pachychoroid Neovasculopathy.
Ophthalmol Ther
September 2025
School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Introduction: This study aimed to evaluate the anatomical and functional outcomes of switching to intravitreally administered brolucizumab (Beovu, Novartis) in patients affected by pachychoroid neovasculopathy (PNV) who were considered as non-responders to previous anti-vascular endothelial growth factor (anti-VEGF) therapies, defined as the persistence of intraretinal fluid (IRF), subretinal fluid (SRF), or subretinal hyper-reflective material (SHRM).
Methods: Twenty-three eyes of 21 patients with exudative PNV, who were switched to brolucizumab between April 2021 and December 2023, were retrospectively enrolled. All patients had previously received at least one injection of another anti-VEGF agent.